Erratum

This article refers to:

Tapentadol immediate release for the relief of moderate-to-severe acute pain

In the drug evaluation “Tapentadol immediate release for the relief of moderate-to-severe acute pain” by Hartrick C published in the November issue of Expert Opinion on Pharmacotherapy (Expert Opin. Pharmacother. 2009;10(16):2687-2696), Box 1 and the credit lines for Tables 2 and 3 and Figure 1 should have appeared as follows:

Box 1. Drug summary.

Drug name	Tapentadol IR
Phase	Launched
Indication	Moderate to severe acute pain
Pharmacology description	μ-Opioid receptor agonist and norepinephrine reuptake inhibitor
Route of administration	Alimentary, p.o.
Chemical structure
Pivotal trial(s)	Four Phase III trials of patients with moderate to severe acute postoperative pain, osteoarthritis pain, and/or low back pain have been conducted. Data suggested that the efficacy of tapentadol IR 50, 75, or 100 mg every 4 – 6 h was similar to that of oxycodone HCl IR 10 or 15 mg every 4 – 6 h with improved gastrointestinal tolerability.

Pharmaprojects - Copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Informa-Pipeline (http://informa-pipeline.citeline.com) and Citeline (http://informa.citeline.com).

Table 2: Adapted by permission from Informa Healthcare: Curr Med Res Opin. 24(11):3185-96 [39]. Copyright 2008 Informa.

Table 3: Adapted by permission from Informa Healthcare: Curr Med Res Opin. 25(6):1551-61 [42]. Copyright 2009 Informa.

Figure 1: Reproduced with permission from Hale, et al. Curr Med Res Opin. 2009;25(5):1095-104 [41].

The publishers, editors and author regret any inconvenience this may have caused.